These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 15081035

  • 1. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.
    Lin LS, Lanza TJ, Castonguay LA, Kamenecka T, McCauley E, Van Riper G, Egger LA, Mumford RA, Tong X, MacCoss M, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2004 May 03; 14(9):2331-4. PubMed ID: 15081035
    [Abstract] [Full Text] [Related]

  • 2. A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.
    Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.
    Bioorg Med Chem; 2009 Feb 01; 17(3):1232-43. PubMed ID: 19124247
    [Abstract] [Full Text] [Related]

  • 3. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
    Witherington J, Blaney EL, Bordas V, Elliott RL, Gaiba A, Garton N, Green PM, Naylor A, Smith DG, Spalding DJ, Takle AK, Ward RW.
    Bioorg Med Chem Lett; 2006 Nov 01; 16(21):5538-41. PubMed ID: 16931004
    [Abstract] [Full Text] [Related]

  • 4. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
    Semko CM, Chen L, Dressen DB, Dreyer ML, Dunn W, Farouz FS, Freedman SB, Holsztynska EJ, Jefferies M, Konradi AW, Liao A, Lugar J, Mutter L, Pleiss MA, Quinn KP, Thompson T, Thorsett ED, Vandevert C, Xu YZ, Yednock TA.
    Bioorg Med Chem Lett; 2011 Mar 15; 21(6):1741-3. PubMed ID: 21316228
    [Abstract] [Full Text] [Related]

  • 5. Influence of acid surrogates toward potency of VLA-4 antagonist.
    Venkatraman S, Lim J, Cramer M, Gardner MF, James J, Alves K, Lingham RB, Mumford RA, Munoz B.
    Bioorg Med Chem Lett; 2005 Sep 15; 15(18):4053-6. PubMed ID: 16039122
    [Abstract] [Full Text] [Related]

  • 6. Discovery of potential integrin VLA-4 antagonists using pharmacophore modeling, virtual screening and molecular docking studies.
    Thangapandian S, John S, Sakkiah S, Lee KW.
    Chem Biol Drug Des; 2011 Aug 15; 78(2):289-300. PubMed ID: 21507205
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
    Marugán JJ, Manthey C, Anaclerio B, Lafrance L, Lu T, Markotan T, Leonard KA, Crysler C, Eisennagel S, Dasgupta M, Tomczuk B.
    J Med Chem; 2005 Feb 24; 48(4):926-34. PubMed ID: 15715463
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
    Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N.
    Bioorg Med Chem; 2007 Feb 15; 15(4):1679-93. PubMed ID: 17194595
    [Abstract] [Full Text] [Related]

  • 9. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
    Venkatraman S, Lebsack AD, Alves K, Gardner MF, James J, Lingham RB, Maniar S, Mumford RA, Si Q, Stock N, Treonze KM, Wang B, Zunic J, Munoz B.
    Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5803-6. PubMed ID: 19713111
    [Abstract] [Full Text] [Related]

  • 10. Amidines as amide bond replacements in VLA-4 antagonists.
    Kamenecka TM, Park YJ, Lin LS, de Laszlo S, McCauley ED, Van Riper G, Egger L, Kidambi U, Mumford RA, Tong S, Tang W, Colletti A, Teffera Y, Stearns R, MacCoss M, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2004 May 03; 14(9):2323-6. PubMed ID: 15081033
    [Abstract] [Full Text] [Related]

  • 11. Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.
    Chang LL, Yang GX, McCauley E, Mumford RA, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2008 Mar 01; 18(5):1688-91. PubMed ID: 18242984
    [Abstract] [Full Text] [Related]

  • 12. The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.
    Lin LS, Kopka IE, Mumford RA, Magriotis PA, Lanza T, Durette PL, Kamenecka T, Young DN, de Laszlo SE, McCauley E, Riper GV, Kidambi U, Egger LA, Tong X, Lyons K, Vincent S, Stearns R, Colletti A, Teffera Y, Fenyk-Melody J, Schmidt JA, MacCoss M, Hagmann WK.
    Bioorg Med Chem Lett; 2002 Feb 25; 12(4):611-4. PubMed ID: 11844683
    [Abstract] [Full Text] [Related]

  • 13. Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
    Witherington J, Bordas V, Gaiba A, Green PM, Naylor A, Parr N, Smith DG, Takle AK, Ward RW.
    Bioorg Med Chem Lett; 2006 Apr 15; 16(8):2256-9. PubMed ID: 16455247
    [Abstract] [Full Text] [Related]

  • 14. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.
    Chiba J, Machinaga N, Takashi T, Ejima A, Takayama G, Yokoyama M, Nakayama A, Baldwin JJ, McDonald E, Moriarty KJ, Sarko CR, Saionz KW, Swanson R, Hussain Z, Wong A.
    Bioorg Med Chem Lett; 2005 Jan 03; 15(1):41-5. PubMed ID: 15582407
    [Abstract] [Full Text] [Related]

  • 15. 2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
    Lassoie MA, Broeders F, Collart P, Defrère L, de Laveleye-Defais F, Demaude T, Gassama A, Guillaumet G, Hayez JC, Kiss L, Knerr L, Nicolas JM, Norsikian S, Quéré L, Routier S, Verbois V, Provins L.
    Bioorg Med Chem Lett; 2007 Jan 01; 17(1):142-6. PubMed ID: 17035017
    [Abstract] [Full Text] [Related]

  • 16. Highly constrained bicyclic VLA-4 antagonists.
    Chang LL, Truong Q, Doss GA, MacCoss M, Lyons K, McCauley E, Mumford R, Forrest G, Vincent S, Schmidt JA, Hagmann WK.
    Bioorg Med Chem Lett; 2007 Feb 01; 17(3):597-601. PubMed ID: 17118652
    [Abstract] [Full Text] [Related]

  • 17. Imidazopyridines as VLA-4 integrin antagonists.
    Phillips DJ, Davenport RJ, Demaude TA, Galleway FP, Jones MW, Knerr L, Perry BG, Ratcliffe AJ.
    Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4146-9. PubMed ID: 18539454
    [Abstract] [Full Text] [Related]

  • 18. Characterization of alpha(4)beta(1) (CD49d/CD29) on equine leukocytes: potential utility of a potent alpha(4)beta(1) (CD49d/CD29) receptor antagonist in the treatment of equine heaves (recurrent airway obstruction).
    Treonze KM, Alves K, Fischer P, Hagmann WK, Hora D, Kulick A, Vakerich K, Smith ND, Lingham RB, Maniar S, Reger TS, Zunic J, Munoz B, Prasit P, Nicholson D, Si Q, Judd K, Nicolich S, Kellerhouse P, Thompson D, Mumford RA.
    Vet Immunol Immunopathol; 2009 Jul 15; 130(1-2):79-87. PubMed ID: 19250687
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y, Barbay JK, Dyatkin AB, Miskowski TA, Kimball ES, Prouty SM, Fisher MC, Santulli RJ, Schneider CR, Wallace NH, Ballentine SA, Hageman WE, Masucci JA, Maryanoff BE, Damiano BP, Andrade-Gordon P, Hlasta DJ, Hornby PJ, He W.
    J Med Chem; 2006 Jun 01; 49(11):3402-11. PubMed ID: 16722660
    [Abstract] [Full Text] [Related]

  • 20. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists.
    Chiba J, Takayama G, Takashi T, Yokoyama M, Nakayama A, Baldwin JJ, McDonald E, Moriarty KJ, Sarko CR, Saionz KW, Swanson R, Hussain Z, Wong A, Machinaga N.
    Bioorg Med Chem; 2006 Apr 15; 14(8):2725-46. PubMed ID: 16377201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.